文献速递认知障碍与痴呆

MAPT H2单倍型与皮克病风险:皮克病国际联盟的遗传关联研究

MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study.
PubMed 文献 · Lancet Neurol · 2024-01-01

本研究利用皮克病国际联盟数据,对338例病理确诊皮克病患者和1312名神经健康对照进行遗传关联分析,发现MAPT H2单倍型与皮克病风险增加相关(OR 1.35),但与发病年龄和病程无关。

要点

  • MAPT H2单倍型与皮克病风险增加相关(OR 1.35,95%CI 1.12-1.64,p=0.0021)。
  • MAPT H2与皮克病发病年龄(β -0.54,p=0.45)和病程(β 0.05,p=0.35)无显著关联。
  • MAPT H1f亚单倍型与皮克病风险降低相关(OR 0.11,p=0.049),但未通过多重检验校正。

核心结论

  • 在歐洲血统人群中,MAPT H2单倍型与皮克病风险增加相关,这与四重复tau蛋白病的风险降低相反。

研究设计与样本

  • 遗传关联研究,收集北美、欧洲和澳大利亚35个站点病理确诊的皮克病患者脑样本338例和神经健康对照1312名。

主要发现

  • MAPT H2单倍型与皮克病风险增加相关(OR 1.35,95%CI 1.12-1.64,p=0.0021)。
  • MAPT H2与发病年龄(β -0.54,95%CI -1.94-0.87,p=0.45)和病程(β 0.05,95%CI -0.06-0.16,p=0.35)无显著关联。
  • H1f亚单倍型与皮克病风险相关(OR 0.11,95%CI 0.01-0.99,p=0.049),未通过多重检验校正。
  • H1b、H1i、H1u亚单倍型与发病年龄相关(β分别为2.66、-3.66、-5.25,p<0.05),未通过多重检验校正。
  • H1x亚单倍型与病程相关(β -0.57,95%CI -1.07至-0.07,p=0.026),未通过多重检验校正。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pick's disease is a rare and predominantly sporadic form of frontotemporal dementia that is classified as a primary tauopathy. Pick's disease is pathologically defined by the presence in the frontal and temporal lobes of Pick bodies, composed of hyperphosphorylated, three-repeat tau protein, encoded by the MAPT gene. MAPT has two distinct haplotypes, H1 and H2; the MAPT H1 haplotype is the major genetic risk factor for four-repeat tauopathies (eg, progressive supranuclear palsy and corticobasal degeneration), and the MAPT H2 haplotype is protective for these disorders. The primary aim of this study was to evaluate the association of MAPT H2 with Pick's disease risk, age at onset, and disease duration. METHODS: In this genetic association study, we used data from the Pick's disease International Consortium, which we established to enable collection of data from individuals with pathologically confirmed Pick's disease worldwide. For this analysis, we collected brain samples from individuals with pathologically confirmed Pick's disease from 35 sites (brainbanks and hospitals) in North America, Europe, and Australia between Jan 1, 2020, and Jan 31, 2023. Neurologically healthy controls were recruited from the Mayo Clinic (FL, USA, or MN, USA between March 1, 1998, and Sept 1, 2019). For the primary analysis, individuals were directly genotyped for the MAPT H1-H2 haplotype-defining variant rs8070723. In a secondary analysis, we genotyped and constructed the six-variant-defined (rs1467967-rs242557-rs3785883-rs2471738-rs8070723-rs7521) MAPT H1 subhaplotypes. Associations of MAPT variants and MAPT haplotypes with Pick's disease risk, age at onset, and disease duration were examined using logistic and linear regression models; odds ratios (ORs) and β coefficients were estimated and correspond to each additional minor allele or each additional copy of the given haplotype. FINDINGS: We obtained brain samples from 338 people with pathologically confirmed Pick's disease (205 [61%] male and 133 [39%] female; 338 [100%] White) and 1312 neurologically healthy controls (611 [47%] male and 701 [53%] female; 1312 [100%] White). The MAPT H2 haplotype was associated with increased risk of Pick's disease compared with the H1 haplotype (OR 1·35 [95% CI 1·12 to 1·64], p=0·0021). MAPT H2 was not associated with age at onset (β -0·54 [95% CI -1·94 to 0·87], p=0·45) or disease duration (β 0·05 [-0·06 to 0·16], p=0·35). Although not significant after correcting for multiple testing, associations were observed at p less than 0·05: with risk of Pick's disease for the H1f subhaplotype (OR 0·11 [0·01 to 0·99], p=0·049); with age at onset for H1b (β 2·66 [0·63 to 4·70], p=0·011), H1i (β -3·66 [-6·83 to -0·48], p=0·025), and H1u (β -5·25 [-10·42 to -0·07], p=0·048); and with disease duration for H1x (β -0·57 [-1·07 to -0·07], p=0·026). INTERPRETATION: The Pick's disease International Consortium provides an opportunity to do large studies to enhance our understanding of the pathobiology of Pick's disease. This study shows that, in contrast to the decreased risk of four-repeat tauopathies, the MAPT H2 haplotype is associated with an increased risk of Pick's disease in people of European ancestry. This finding could inform development of isoform-related therapeutics for tauopathies. FUNDING: Wellcome Trust, Rotha Abraham Trust, Brain Research UK, the Dolby Fund, Dementia Research Institute (Medical Research Council), US National Institutes of Health, and the Mayo Clinic Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Valentino RR, Scotton WJ, Roemer SF, et al. MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study. Lancet Neurol. 2024. PMID: 38631765. doi:10.1016/S1474-4422(24)00083-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。